Application of Molecular Genetics for Diagnosing Familial Hypercholesterolemia in Norway: Results from a Family-Based Screening Program

Seminars in Vascular Medicine

Volumn 4, Issue 1, 2004, Pages 75-85

  Leren, Trond P ^a   Manshaus, Turid ^a   Skovholt, Unn ^a   Skodje, Tove ^a   Nossen, Inger Esther ^a   Teie, Christél ^a   Sørensen, Stine ^a   Bakken, Kari Solberg ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Familial hypercholesterolemia; Genetics; Low density lipoprotein receptor; Mutation

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADOLESCENT; ADULT; CHILD; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC VALUE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; NORWAY; RECEPTOR GENE; REVIEW; XANTHOMA;

BIOLOGICAL MARKERS; DISEASE MANAGEMENT; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MOLECULAR BIOLOGY; NORWAY;

EID: 1642364524     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822989     Document Type: Review

References (13)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Baudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill; 2001:2863-2913
2. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-1382
3. Williams RR, Hamilton-Craig I, Kostner GM, et al. MED PED: an integrated genetic strategy for preventing early deaths. In: Berg K, Boulyjenkov V, Christen Y, eds. Genetic Approaches to Noncommunicable Diseases. Berlin: Springer; 1996:35-46
4. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, et al. Review of the first 5 years of screening for familial hypercholesterolemia in the Netherlands. Lancet 2001;357: 165-168
5. Wood D, De Backer G, Faergeman O, et al, Prevention of coronary heart disease in clinical practice: recommendation of the second task force of European and other societies on coronary prevention. Atherosclerosis 1998;140:199-270
6. Leren TP, Tonstad S, Rødningen OK, et al. Molecular genetics of familial hypercholesterolemia in Norway. J Intern Med 1997;241:185-194
7. Heiberg A, Berg K. The inheritance of hyperlipoproteinemia with xanthomatosis. A study of 132 kindreds. Clin Genet 1976;9:203-233
8. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001;109:602-615
9. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989;86:587-591
10. Eiken HG, Odland E, Boman H, et al. Application of natural and amplification created restriction sites for the diagnosis of PKU mutations. Nucleic Acids Res 1991;19:1427-1430
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502
12. Umans-Eckenhausen MAW, Sijbrands EJG, Kastelein JJP, et al. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002;106:3031-3036
13. Umans-Eckenhausen MAW, Defesche JC, van Dam MJ, et al. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003;163:65-68